Revance Therapeutics, Inc. (NASDAQ:RVNC) currently has an Average Broker Rating of 1. The ABR rank within the industry stands at 10. This number is based on the 6 sell-side firms polled by Zacks.
Each brokerage research report carries with it some form of recommendation. The brokerage firms may use different lingo for their rating systems (like saying Outperform instead of Buy), but they can all be properly sorted into our 5 level classification system that is now the industry standard. Each of the 5 classifications has a value associated with it to help compute the ABR.
As the name implies the ABR will show you the Average of Brokerage Recommendations on a given stock. The benefit is that you quickly get a snapshot of where Wall Street stands on a stock without having to read a mountain of research reports.
Broker recommendations are made by brokerage firms (for example, JP Morgan) and are not an outright recommendation to buy or sell a share, but instead give an indication of how the broker thinks the company will perform relative to its sector. Their recommendations are issued over a particular period of time. The recommendations provided in the Research Centre are shown on a 75 day rolling basis. Each brokerage firm has its own way of rating that may make it difficult to compare broker recommendations between the brokerage houses.
For example, at one brokerage “buy” may be the strongest recommendation, while at another “buy” could be second to a “strong buy” rating. The second-highest ratings also have a number of different other names: “accumulate”, “outperform”, “moderate buy” or “overweight”.
Analysts on a consensus basis are expecting that the stock will reach $39.8 within the year.
Following a pre-defined trading system might be a solid choice for securing profits in the stock market. Defining goals before creating a plan can be a good way to start the trader off on the right path. There are bound to be many ups and downs throughout the trading process. Being able to manage wins and losses may be one of the most important factors to becoming a successful trader. Without a researched plan, traders may realize how quick the losses can pile up. Properly managing risk, position size, entry and exit points, and stops, may come with experience, but it is typically necessary in order to stay above water in the fast paced market environment.
Research analysts are predicting that Revance Therapeutics, Inc. (NASDAQ:RVNC) will report earnings of $-0.95 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.
Revance Therapeutics, Inc. (NASDAQ:RVNC) closed the last session at $25.35 and sees an average of 141217.55 shares trade hands in each session. The 52-week low of the stock stands at $16.15 while the current level stands at 75.72% of the 52-week High-Low range. Looking further out we can see that the stock has moved 9.27% over the past 12 weeks and 22.46% year to date.
Most recently Revance Therapeutics, Inc. (NASDAQ:RVNC) posted quarterly earnings of $-1.01 which compared to the sell-side estimates of -0.93. The stock’s 12-month trailing earnings per share stands at $-3.8. Shares have moved $-2.87 over the past month and more recently, $-5.41 over the past week heading into the earnings announcement. There are 3 analyst projections that were taken into consideration from respected brokerage firms.
Individual investors often have a lot to deal with when surveying the stock market landscape. Choosing stocks based on recent performance may not work out as well as planned. Stocks that were winners last year, last month, or even last week, may not be winners next week, next month, or next year. Digging into the fundamentals can help the investor see what stocks are set up for future success. Taking multiple approaches when viewing a certain security may help the investor put the puzzle together and see the bigger picture. Staying current on economic data can also help the investor obtain a broader sense of what is driving present market conditions.
6 analysts rate Revance Therapeutics, Inc. a Buy or Strong Buy, which is 100% of all the analyst ratings.